A Phase 1, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD), First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy ofmEphA4-Fc in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis (ALS)